Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 plus adebrelimab vs docetaxel in advanced non-squamous NSCLC after platinum therapy
CTR20260641Phase 3Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risvutatug rezetecan in Non-small cell lung cancer (NS-NSCLC), sponsored by Hansoh Pharmaceutical Group. Started Mar 2026; status: active.
02
Drugs
risvutatug rezetecan
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20260641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260641.